

# Rodney H Falk

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3989720/rodney-h-falk-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57  
papers

4,585  
citations

30  
h-index

67  
g-index

69  
ext. papers

6,055  
ext. citations

6.9  
avg, IF

5.88  
L-index

#	Paper	IF	Citations
57	Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. <i>American Journal of Hematology</i> , <b>2005</b> , 79, 319-28	7.1	971
56	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. <i>Circulation</i> , <b>2016</b> , 133, 2404-12	16.7	792
55	Diagnosis and management of the cardiac amyloidoses. <i>Circulation</i> , <b>2005</b> , 112, 2047-60	16.7	551
54	AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 1323-41	15.1	277
53	Amyloid heart disease. <i>Progress in Cardiovascular Diseases</i> , <b>2010</b> , 52, 347-61	8.5	165
52	Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 285-295	15.1	108
51	Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. <i>JACC: Heart Failure</i> , <b>2014</b> , 2, 358-67	7.9	100
50	Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 709-716	7.9	97
49	Cardiac amyloidosis: a treatable disease, often overlooked. <i>Circulation</i> , <b>2011</b> , 124, 1079-85	16.7	95
48	Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 519-26	7.6	90
47	How to image cardiac amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , <b>2014</b> , 7, 552-62	3.9	89
46	18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study. <i>Circulation: Cardiovascular Imaging</i> , <b>2015</b> , 8,	3.9	78
45	Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. <i>EMBO Molecular Medicine</i> , <b>2014</b> , 6, 1493-507	12	74
44	Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 962-963	27.4	71
43	How to Image Cardiac Amyloidosis: A Practical Approach. <i>JACC: Cardiovascular Imaging</i> , <b>2020</b> , 13, 1368-1833	7.6	69
42	Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. <i>Heart Rhythm</i> , <b>2016</b> , 13, 383-90	6.7	66
41	Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e005407	7.6	58

40	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. <i>Journal of Cardiac Failure</i> , <b>2019</b> , 25, e1-e39	3.3	56
39	Left atrial structure and function in cardiac amyloidosis. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2017</b> , 18, 1128-1137	4.1	50
38	Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2851-2862	15.1	50
37	Prevalence of Monoclonal Gammopathy in Wild-Type Transthyretin Amyloidosis. <i>Mayo Clinic Proceedings</i> , <b>2017</b> , 92, 1800-1805	6.4	45
36	Echocardiography in cardiac amyloidosis. <i>Heart Failure Reviews</i> , <b>2015</b> , 20, 125-31	5	45
35	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. <i>Journal of Cardiac Failure</i> , <b>2019</b> , 25, 854-865	3.3	40
34	Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 466-472	16.2	40
33	Characterization of Cardiac Amyloidosis by Atrial Late Gadolinium Enhancement Using Contrast-Enhanced Cardiac Magnetic Resonance Imaging and Correlation With Left Atrial Conduit and Contractile Function. <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 622-9	3	38
32	State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. <i>Journal of Nuclear Cardiology</i> , <b>2019</b> , 26, 158-173	2.1	38
31	Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). <i>Cardiovascular Drugs and Therapy</i> , <b>2020</b> , 34, 357-370	3.9	34
30	Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015: Potential Underdetection of Cardiac Amyloidosis. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 865-870	16.2	34
29	Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body F-Florbetapir PET/CT. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 1234-1239	8.9	30
28	Novel pharmacotherapies for cardiac amyloidosis. <i>Pharmacology &amp; Therapeutics</i> , <b>2017</b> , 180, 129-138	13.9	21
27	Relative Apical Sparing of Myocardial Longitudinal Strain Is Explained by Regional Differences in Total Amyloid Mass Rather Than the Proportion of Amyloid Deposits. <i>JACC: Cardiovascular Imaging</i> , <b>2019</b> , 12, 1165-1173	8.4	19
26	Senile systemic amyloidosis: are regional differences real or do they reflect different diagnostic suspicion and use of techniques?. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2012</b> , 19 Suppl 1, 68-70	2.7	19
25	Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?. <i>European Heart Journal</i> , <b>2019</b> , 40, 1009-1012	9.5	15
24	Absolute Quantitation of Cardiac Tc-Pyrophosphate Using Cadmium-Zinc-Telluride-Based SPECT/CT. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 716-722	8.9	13
23	Amyloidosis as a Systemic Disease in Context. <i>Canadian Journal of Cardiology</i> , <b>2020</b> , 36, 396-407	3.8	12

22	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. <i>Circulation: Cardiovascular Imaging</i> , <b>2021</b> , 14, e000029	3.9	12
21	Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	9
20	Quantitative [F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 1998-2009	8.8	7
19	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. <i>Circulation: Cardiovascular Imaging</i> , <b>2021</b> , 14, e000030	3.9	6
18	SA new staging system for cardiac transthyretin amyloidosisS is it already on the verge of obsolescence?. <i>European Heart Journal</i> , <b>2018</b> , 39, 2807-2809	9.5	5
17	Left atrial structure and function of the amyloidogenic V122I transthyretin variant inElderly African Americans. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1290-1295	12.3	5
16	Role of Imaging in Evaluating Infiltrative Heart Disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2017</b> , 19, 3	2.1	4
15	True, true unrelated? Coexistence of Waldenström macroglobulinemia and cardiac transthyretin amyloidosis. <i>Haematologica</i> , <b>2018</b> , 103, e374-e376	6.6	4
14	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. <i>Journal of Nuclear Cardiology</i> , <b>2021</b> , 28, 1769-1774	2.1	4
13	Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial PatientsWith Transthyretin AmyloidCardiomyopathy. <i>JACC: CardioOncology</i> , <b>2021</b> , 3, 580-586	3.8	3
12	Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis.. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2022</b> ,	4.1	3
11	Multimodality Imaging in the Evaluation and Management of Cardiac Amyloidosis. <i>Seminars in Nuclear Medicine</i> , <b>2020</b> , 50, 295-310	5.4	2
10	Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.. <i>BMC Cardiovascular Disorders</i> , <b>2022</b> , 22, 49	2.3	1
9	Rhabdomyolysis in the Setting of Concomitant Use of Tafamidis, Atorvastatin, and Amiodarone. <i>JACC: Case Reports</i> , <b>2020</b> , 2, 2372-2375	1.2	1
8	Initial Monthly Cost of Tafamidis-the Real Price for Patients. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 847-848	16.2	1
7	High sensitivity M-protein detection in a case of light-chain cardiac amyloidosis without evidence of plasma cell dyscrasia. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 619-621	7.1	1
6	Imaging cardiac amyloidosis: Patient page. <i>Journal of Nuclear Cardiology</i> , <b>2019</b> , 26, 217-221	2.1	1
5	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. <i>Journal of Cardiac Failure</i> , <b>2021</b> ,	3.3	1

## LIST OF PUBLICATIONS

4	Geographic variation in public interest about amyloidosis in the United States and English speaking countries. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2020</b> , 27, 210-212	2.7	o
3	Complexities and Pitfalls in Cardiac Amyloidosis. <i>Circulation</i> , <b>2020</b> , 142, 409-415	16.7	o
2	Molecular Imaging of Cardiac Amyloidosis. <i>Current Cardiovascular Imaging Reports</i> , <b>2018</b> , 11, 1	0.7	
1	Letter by Falk et al Regarding Article, "False-Positive Technetium-Pyrophosphate Scintigraphy in Two Patients With Hypertrophic Cardiomyopathy".. <i>Circulation: Heart Failure</i> , <b>2022</b> , 101161CIRCHEARTFAILURE121008	7.6	